Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma - PubMed (original) (raw)
Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma
S W Grant et al. Cancer Detect Prev. 1998.
Abstract
On the basis of reports linking mutant p53 (mp53) to decreased expression of the angiogenesis inhibitor thrombospondin-1 (TSP-1) and increased angiogenesis, we compared primary and metastatic melanoma tumor specimens to determine if these factors were associated with metastatic progression. Western blotting, immunohistochemistry (IHC), and image analysis (IA) techniques were employed to evaluate the relationship between p53 status and TSP-1 expression in Zaz and M14 melanoma cell lines, and among p53, TSP-1, and angiogenesis in primary and metastatic melanomas. Zaz cells expressed wild-type p53 (WT p53) and high levels of TSP-1, while the M14 cells expressed mp53 and low TSP-1 levels. Examination of clinical melanoma specimens (N = 99) revealed an incidence of mp53 of 48%. Specimens with WT p53 (N = 46) expressed significantly higher mean levels of TSP-1 (41 +/- 27 vs. 21 +/- 24; p = 0.0004), and lower microvessel counts per 200x field (25 +/- 17 vs. 40 +/- 20; p = 0.0001) than tumors expressing mp53 (N = 42). A significantly higher incidence of mp53 expression was seen in metastatic tumors (64%, 37/58) than in primary tumors (27%, 11/41)(p < 0.0005). Primary tumors specimens had higher levels of TSP-1 (40 +/- 27 vs. 25 +/- 25; p = 0.0054) and lower microvessel counts (26 +/- 18 vs. 39 +/- 20, p = 0.0013) than metastatic tumors. These data suggest that acquisition of mp53, decreased TSP-1, and increased microvessel infiltration may be interrelated and associated with the metastatic phenotype in malignant melanoma.
Similar articles
- Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.
Iddings DM, Koda EA, Grewal SS, Parker R, Saha S, Bilchik A. Iddings DM, et al. Arch Surg. 2007 Aug;142(8):738-44; discussion 744-5. doi: 10.1001/archsurg.142.8.738. Arch Surg. 2007. PMID: 17709727 - Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression.
Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, Cote RJ. Grossfeld GD, et al. J Natl Cancer Inst. 1997 Feb 5;89(3):219-27. doi: 10.1093/jnci/89.3.219. J Natl Cancer Inst. 1997. PMID: 9017002 - Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
Fontanini G, Boldrini L, Calcinai A, Chinè S, Lucchi M, Mussi A, Angeletti CA, Basolo F, Bevilacqua G. Fontanini G, et al. Clin Cancer Res. 1999 Jan;5(1):155-61. Clin Cancer Res. 1999. PMID: 9918214 - Mutation and expression of TP53 in malignant melanomas.
Weiss J, Heine M, Arden KC, Körner B, Pilch H, Herbst RA, Jung EG. Weiss J, et al. Recent Results Cancer Res. 1995;139:137-54. doi: 10.1007/978-3-642-78771-3_10. Recent Results Cancer Res. 1995. PMID: 7597286 Review. - P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection.
Bristow RG, Brail L, Jang A, Peacock J, Chung S, Benchimol S, Hill RP. Bristow RG, et al. Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):341-55. doi: 10.1016/0360-3016(95)02023-3. Int J Radiat Oncol Biol Phys. 1996. PMID: 8567335 Review.
Cited by
- Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.
Fruehauf JP, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz JG. Fruehauf JP, et al. Cancer Chemother Pharmacol. 2018 Aug;82(2):353-360. doi: 10.1007/s00280-018-3624-6. Epub 2018 Jun 25. Cancer Chemother Pharmacol. 2018. PMID: 29943192 Free PMC article. Clinical Trial. - The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.
A Y, Li Y, Zhao S. A Y, et al. Oncol Lett. 2018 Feb;15(2):2534-2540. doi: 10.3892/ol.2017.7580. Epub 2017 Dec 11. Oncol Lett. 2018. PMID: 29434970 Free PMC article. - From melanocytes to melanomas.
Shain AH, Bastian BC. Shain AH, et al. Nat Rev Cancer. 2016 Jun;16(6):345-58. doi: 10.1038/nrc.2016.37. Epub 2016 Apr 29. Nat Rev Cancer. 2016. PMID: 27125352 Review. - Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.
Miyata Y, Sakai H. Miyata Y, et al. Int J Mol Sci. 2013 Jun 7;14(6):12249-72. doi: 10.3390/ijms140612249. Int J Mol Sci. 2013. PMID: 23749112 Free PMC article. Review. - Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts.
Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, Armstrong EA, Blitzer GC, Smith MA, Lorenz LD, Lee D, Yang DT, McCulloch TM, Hartig GK, Lambert PF. Kimple RJ, et al. Clin Cancer Res. 2013 Feb 15;19(4):855-64. doi: 10.1158/1078-0432.CCR-12-2746. Epub 2012 Dec 18. Clin Cancer Res. 2013. PMID: 23251001 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous